
Sign up to save your podcasts
Or


You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than eight months ago. Well, bird flu is still here and the number of reported cases in people is growing. STAT’s infectious disease reporter Helen Branswell joins us for an update. But first, we break down the results from a GLP-1 showdown study that compared Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy. Allison shares her recent reporting on a talent shortage that is posing new challenges to the fast-growing radiopharmaceutical industry.
By STAT4.5
309309 ratings
You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than eight months ago. Well, bird flu is still here and the number of reported cases in people is growing. STAT’s infectious disease reporter Helen Branswell joins us for an update. But first, we break down the results from a GLP-1 showdown study that compared Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy. Allison shares her recent reporting on a talent shortage that is posing new challenges to the fast-growing radiopharmaceutical industry.

30,667 Listeners

1,896 Listeners

499 Listeners

9,529 Listeners

6,072 Listeners

395 Listeners

61 Listeners

86 Listeners

34 Listeners

505 Listeners

5,472 Listeners

19 Listeners

48 Listeners

388 Listeners

12 Listeners